We are live on ! Find out more
LVTX

LAVA Therapeutics

Delisted

LVTX was delisted on the 20th of November, 2025.

20 hedge funds and large institutions have $10.2M invested in LAVA Therapeutics in 2025 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

66% more capital invested

Capital invested by funds: $6.15M → $10.2M (+$4.06M)

5.98% more ownership

Funds ownership: 24.62%30.6% (+6%)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

0% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 3

9% less funds holding

Funds holding: 2220 (-2)

25% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 8

Holders
20
Holders Change
-2
Holders Change %
-9.09%
% of All Funds
0.27%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
6
Increased
3
Reduced
3
Closed
8
Calls
$68K
Puts
Net Calls
+$68K
Net Calls Change
+$68K
Name Holding Trade Value Shares
Change
Change in
Stake
TSS
26
Two Sigma Securities
New York
-$12.5K -13,157 Closed
CIBC Private Wealth Group
27
CIBC Private Wealth Group
Georgia
-$6.12K -6,000 Closed
Northwestern Mutual Wealth Management
28
Northwestern Mutual Wealth Management
Wisconsin
-$19 -20 Closed

LVTX Hedge Fund Activity: Q1 2025 in Review

20 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in LAVA Therapeutics (LVTX) for Q1 2025, worth a combined $10.2M — up 66% from $6.15M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of LVTX and 6 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 3 added.

The largest buyer was BML Capital Management, opening a new position worth an estimated $2.18M. The largest seller was Bruce & Co, cutting an estimated $278K.

  • 20 institutional investors held LAVA Therapeutics (LVTX) as of Q1 2025, down from 22 in Q4 2024.
  • Funds reported $10.2M of LAVA Therapeutics stock for Q1 2025, up 66% quarter-over-quarter.
  • 6 funds opened new LAVA Therapeutics positions in Q1 2025 and 8 closed out, a net change of -2 holders.
  • The largest LAVA Therapeutics buyer in Q1 2025 was BML Capital Management, an estimated $2.18M added.
  • The largest LAVA Therapeutics seller in Q1 2025 was Bruce & Co, an estimated $278K sold.

Based on aggregated 13F filings for Q1 2025.